|
MechanismKRAS G12C inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Kanglong Huacheng (Ningbo) Biomedical Co., Ltd.
0 Patents (Medical) associated with Kanglong Huacheng (Ningbo) Biomedical Co., Ltd.
100 Deals associated with Kanglong Huacheng (Ningbo) Biomedical Co., Ltd.
100 Translational Medicine associated with Kanglong Huacheng (Ningbo) Biomedical Co., Ltd.